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504Objective: Extracorporeal membrane oxygenation has been used to support children with cardiac failure after
the Fontan operation. Mortality is high, and causes of mortality remain unclear. We evaluated the in-hospital
mortality and factors associated with mortality in these patients.
Methods: Extracorporeal Life Support Organization registry data on patients requiring extracorporeal mem-
brane oxygenation after the Fontan operation from 1987 to 2009 were retrospectively analyzed. Demographics
and extracorporeal membrane oxygenation data were compared for survivors and nonsurvivors. A multivariable
logistic regression model was used to identify factors associated with mortality.
Results: Of 230 patients, 81 (35%) survived to hospital discharge. Cardiopulmonary resuscitation was more
frequent (34% vs 17%, P ¼ .04), and median fraction of inspired oxygen concentration was higher (1 [confi-
dence interval, 0.9–1.0] vs 0.9 [confidence interval, 0.8–1.0], P¼ .03) before extracorporeal membrane oxygen-
ation in nonsurvivors compared with survivors. Extracorporeal membrane oxygenation duration and incidence
of complications, including surgical bleeding, neurologic injury, renal failure, inotrope use on extracorporeal
membrane oxygenation, and bloodstream infection, were higher in nonsurvivors compared with survivors
(P< .05 for all). In a multivariable model, neurologic injury (odds ratio, 5.18; 95% confidence interval,
1.97–13.61), surgical bleeding (odds ratio, 2.36; 95% confidence interval, 1.22–4.56), and renal failure (odds
ratio, 2.81; 95% confidence interval, 1.41–5.59) increasedmortality. Extracorporeal membrane oxygenation du-
ration of more than 65 hours to 119 hours (odds ratio, 0.33; 95% confidence interval, 0.14–0.76) was associated
with decreased mortality.
Conclusions: Cardiac failure requiring extracorporeal membrane oxygenation after the Fontan operation is as-
sociated with high mortality. Complications during extracorporeal membrane oxygenation support increase
mortality odds. Prompt correction of surgical bleeding when possible may improve survival. (J Thorac Cardi-
ovasc Surg 2011;142:504-10)Extracorporeal membrane oxygenation (ECMO) has been
used to provide mechanical circulatory support for patients
with congenital or acquired cardiac disease in cardiac fail-
ure when conventional medical management has failed.
ECMO has been used with increasing frequency to support
the postoperative patient with cardiac failure after repair or
palliation of congenital heart disease.1-9 Indications for
ECMO support in the postoperative period include severe
cardiac dysfunction from postcardiotomy cardiac failure,
hemodynamically unstable and refractory arrhythmias,
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The Journal of Thoracic and Cardiovascular Surg(extracorporeal cardiopulmonary resuscitation [ECPR]) as
a bridge to recovery or transplantation.8-12 Morbidity and
mortality associated with ECMO use are high; survival in
children with heart disease requiring ECMO support is
reported to be 33% to 60%.1-5,8,10-12 Factors associated with
mortality in children supported with ECMO after cardiac
surgery for congenital heart disease remain variable.1-8,11
The Fontan procedure is an established surgical palliation
procedure for single ventricle cardiac anomalies in which
completion of a total cavopulmonary connection is
achieved by anastomosis of the inferior vena cava to the pul-
monary arteries, thus allowing passive return of all systemic
venous blood into the pulmonary circulation.13 The use of
ECMO to support severe cardiac dysfunction in children
with the Fontan circulation has been reported.14 However,
current knowledge of outcomes after ECMO support in
this population is limited to case reports and small single-
center series. It is therefore difficult to draw inferences re-
garding the applicability of ECMO for support of severe
cardiac dysfunction in this population.4-7,10,11,15-18
The purpose of this study was to use a large multi-
institutional data set to better evaluate in-hospital mortalityery c September 2011
Abbreviations and Acronyms
CI ¼ confidence interval
CNS ¼ central nervous system
CPR ¼ cardiopulmonary resuscitation
CPT ¼ Common Procedural Technology
ECMO ¼ extracorporeal membrane oxygenation
ECPR ¼ extracorporeal cardiopulmonary
resuscitation
ELSO ¼ Extracorporeal Life Support
Organization
HLHS ¼ hypoplastic left heart syndrome
IQR ¼ interquartile range
IRB ¼ institutional review board
OR ¼ odds ratio
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Dfor children with severe cardiac failure requiring ECMO
support after the Fontan operation. We aimed to identify
factors associated with mortality to potentially direct man-
agement decisions and to help improve patient outcomes.MATERIALS AND METHODS
Data Source
Data for this study were obtained from the Extracorporeal Life Support
Organization’s (ELSO) data registry. The ELSO registry collects data on
ECMO used for purposes of supporting critically ill patients with cardiore-
spiratory failure from all indications. Data are reported to the registry from
116 reporting centers, including 14 international centers. Data are collected
using a standardized data-collection form containing patient demographic
information, diagnosis, and procedures at the time of ECMO onset and at
death or discharge, information regarding the indication and conduct of
ECMO including details of equipment used, ECMO complications and sur-
vival to hospital discharge, and discharge disposition. Data reported to the
registry are approved at each member institution by their local internal sci-
entific institutional review board (IRB). Waiver of patient consent for data
reporting to ELSO is institution dependent and governed by their local IRB.
The registry’s data user agreement allows individual member centers to ob-
tain de-identified data for purposes of research and scientific publication
without the need for additional IRB approval.
For purposes of this study we extracted data for all patients receiving
ECMO who had a primary procedure diagnosis code for the Fontan oper-
ation (Common Procedural Technology [CPT] code 33615 [simple Fontan]
or 33617 [Fontan operation]). The primary procedure code details patient
procedures during the index hospital admission before onset of ECMO.
Patient demographic information, primary and secondary diagnosis and
procedures, indication for ECMO, pre-ECMO support, pre-ECMO blood
gases and ventilator settings, details of ECMO course and duration of
ECMO, ECMO complications, survival to hospital discharge, and
discharge disposition data were extracted.
Data Categorization
International Classification for Diseases 9th Revision code for hypo-
plastic left heart syndrome (HLHS; 746.7) was used to categorize patients
into those with HLHS and non-HLHS using their reported primary and sec-
ondary diagnosis codes. Arterial and venous cannulation sites reported for
conduct of ECMO were used to categorize access into thoracic or periph-
eral vessel cannulation. Patients with a cannulation site reported as eitherThe Journal of Thoracic and Ca‘‘aorta’’ or ‘‘right atrium’’ were considered to be cannulated via the tho-
racic route. Secondary procedural codes and discharge procedure CPT co-
des for heart transplantation (CPT code 33945) were used to identify
patients who underwent cardiac transplantation before hospital discharge.
ECMO complications were categorized using codes created by the
ELSO registry for the explicit purpose of reporting complications. We cat-
egorized complications as follows: 1. Mechanical complications: defined
as mechanical failure of an ECMO circuit component, report of circuit
air embolus, or mechanical problems related to the cannula; 2. Circuit
thrombus: included the report of thrombus in any area of the ECMO circuit;
3. Surgical bleeding: defined as bleeding from the surgical site or cannula-
tion requiring an intervention with transfusion or surgical intervention; 4.
Neurologic injury (central nervous system [CNS] injury): defined as the
presence of a clinical diagnosis of brain death, clinical or electroencepha-
lographic evidence of seizures, or radiologic evidence (head ultrasound or
computed tomography) of cerebral infarction or bleeding; 5. Renal failure:
defined as serum creatinine greater than 1.5 mg/dL regardless of age or
need for renal replacement therapy; 6. ECMO-related complications:
included continued need for inotropic support while on ECMO, need for
cardiopulmonary resuscitation (CPR) while on ECMO, and continued
metabolic acidosis defined as pH less than 7.2 despite ECMO support; 7.
Cardiac complications: included cardiac arrhythmia during ECMO support
requiring treatment and cardiac tamponade requiring intervention; 8.
Respiratory complications: defined as pulmonary hemorrhage or pneumo-
thorax requiring drainage during ECMO support; 9. Infectious complica-
tions: included culture-proven bloodstream infection; 10. Metabolic
complications: included hypoglycemia defined as a blood glucose level
less than 40 mg/dL for all ages, and hyperglycemia defined as blood glu-
cose level greater than 240 mg/dL for all ages; and 11. Gastrointestinal
complications: defined as gastrointestinal hemorrhage requiring interven-
tion or hyperbilirubinemia defined as total serum bilirubin total greater
than 15 mg/dL, indirect bilirubin greater than 13 mg/dL, or direct bilirubin
greater than 2 mg /dL. For purposes of purposes of this study, we defined
mortality as death before hospital discharge from the institution providing
ECMO support. The ELSO registry does not collect information regarding
timing of ECMO use after the index operation, pre-Fontan operation hemo-
dynamic data, type of Fontan operation (lateral tunnel or extracardiac con-
duit), information regarding the use of a fenestration in the Fontan pathway,
functional neurologic outcomes at discharge, quality of life information for
survivors, and longer-term survival data; thus, these data were not available
for analysis.Statistical Analysis
Demographic, pre-ECMO, ECMO support data, and ECMO complica-
tions were compared for survivors and nonsurvivors. The Mann–Whitney
U test was used to compare continuous variables, and the chi-square test
was used to compare categoric data between the two groups. The Fisher ex-
act test was used for comparison of categoric data when the expected value
in more than 25% of cells was less than 5. A multivariable logistic regres-
sion model was used to evaluate factors associated with mortality for
patients receiving ECMO support after the Fontan operation. Candidate de-
mographic, pre-ECMO, ECMO, and ECMO complications variables were
selected if their univariate P value comparing survivors and nonsurvivors
was less than .1. Candidate variables were entered in the logistic regression
model using the forward selection procedure. Variables were retained in the
model if their adjusted P value was less than .05. Continuous variables re-
tained in the multivariable model were tested for the presence of linearity in
their association with mortality by categorizing the variable based on the
quartile values of their distribution and re-entering the categorized variable
into the model. Demonstration of a linear increase or decrease in odds ratio
(OR) across categories was considered essential to satisfy criteria for line-
arity. Continuous variables not meeting the linearity criteria were retained
in their categoric form. For patients with multiple ECMO runs (n¼ 2), only
information from the first ECMO run was included in the analysis. Data arerdiovascular Surgery c Volume 142, Number 3 505
FIGURE 1. Trends in use and survival for patients supported with ECMO after the Fontan operation. Linear trend P value for survival ¼ .03 indicating
improved survival over time. ECMO, Extracorporeal membrane oxygenation.
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number (%). All authors had access to the data and agreewith data analysis
and interpretation as presented.TABLE 1. Demographic features of study population
Variable
Survivors
n ¼ 81
Nonsurvivors
n ¼ 149 P value
Age (y) 3 (2–4) 3 (2–5) .69
Weight (kg) 13 (11–16) 13 (11–16) .55
Gender (male) 50 (62%) 93 (62%) .75
Race .11*
White 43 (53) 50 (34)
Black 9 (11) 14 (9)
Other 13 (16) 34 (23)
Missing 16 (20) 51 (34)
HLHS diagnosis 26 (32) 39 (26) .34
Year of ECMO .14
1987–1991 6 (7) 23 (15)
1992–1996 9 (11) 22 (15)
1997–2001 15 (19) 34 (23)
2002–2006 37 (46) 46 (31)
2007–2009 14 (17) 24 (16)
HLHS, Hypoplastic left heart syndrome. *P values exclude comparison of missing
patients.RESULTS
Study Population
A total of 232 ECMO runs (230 patients) were identified
in the ELSO registry from 1987 to 2009 in patients with
a primary procedure code for the Fontan operation. Median
age was 3 years (IQR: 2, 5) and weight was 13 kg (IQR: 11,
16). Indications for ECMO included cardiac failure in the
majority of patients (n ¼ 196; 85%), respiratory failure
(n ¼ 12; 5%), and ECMO to support CPR (E-CPR;
n ¼ 22; 10%). Time from endotracheal intubation to onset
of ECMO flow was 25 hours (IQR: 12, 54). The majority of
patients (n ¼ 225; 98%) were supported with venoarterial
ECMO. A combination mode (venoarterial followed by
veno-venous) was used in 1 patient, and 4 patients were can-
nulated with ‘‘other’’ mode. Cannulation sites for ECMO
included open chest thoracic cannulation in 100 patients
(43%) and peripheral vessel cannulation in 56 patients
(24%). Documentation of cannulation site was not avail-
able in the remaining patients.
In-hospital mortality for this cohort was 65% (n ¼ 149).
ECMOwas successfully weaned in 128 patients (56%), but
only 81 patients (35%) survived to hospital discharge.
ECMO was used primarily as a bridge to transplantation
in 16 patients; 5 patients had successful transplants, and 4
patients survived to hospital discharge. The number of pa-
tients supported with ECMO after the Fontan operation in-
creased over time. A statistically significant improvement
in survival for patients supported with ECMO after the Fon-506 The Journal of Thoracic and Cardiovascular Surgtan operation during the study period (chi-square P value
for linear trend: .03; Figure 1) was observed.
Extracorporeal Membrane Oxygenation Survivors
and Nonsurvivors
Demographic data. Table 1 shows the differences in
demographic features of survivors and nonsurvivors in the
study population. Patient age, weight, gender, race, and
year of ECMO use did not vary significantly between survi-
vors and nonsurvivors. Indications for ECMO, including re-
spiratory, cardiac, and ECPR, did not differ significantly
between survivors and nonsurvivors.ery c September 2011
TABLE 2. Pre-extracorporeal membrane oxygenation and
extracorporeal membrane oxygenation features of patients supported
with extracorporeal membrane oxygenation after the Fontan operation
Variable
Survivors
n ¼ 81
Nonsurvivors
n ¼ 149
P
value
Pre-ECMO support
Inotrope use 54 (67%) 90 (60) .35
Cardiac pacing 6 (7) 17 (11) .33
Inhaled nitric oxide 24 (30) 32 (22) .17
HFOV 2 (3) 6 (4) .72*
Bicarbonate replacement 21 (26) 36 (24) .77
NMB use 41 (51%) 59 (40) .11
Pre-ECMO cardiac arrest 17 (21) 51 (34) .04
ECMO indication .51
Respiratory 3 (4) 9 (6)
Cardiac 72 (89) 124 (83)
ECPR 6 (7) 16 (11)
Bridge to cardiac transplant 6 (7) 10 (7) .84
Pre-ECMO arterial blood gas
pH 7.3 (7.23–7.37) 7.33 (7.21–7.41) .32
PaCO2 (mm Hg) 44 (33–53) 42 (34–53) .75
PAO2 (mm Hg) 55 (39–74) 48 (39–74) .31
Standardized bicarbonate
(mmol/L)
21 (19–24) 22 (19–25) .56
Pre-ECMO ventilator settings
FIO2 0.98 (0.80–1.0) 1.0 (0.9–1.0) .03
PIP (cm of H2O) 29 (23–35) 30 (26–36) .14
PEEP (cm of H2O) 4 (3–6) 5 (3–6) .33
MAP (cm of H2O) 10 (9–16) 12 (10–15) .32
Hemodynamics before ECMO
Systolic blood pressure
(mm Hg)
60 (54–69) 61 (50–75) .38
Diastolic blood pressure
(mm Hg)
36 (30–47) 39 (32–49) .28
Mean blood pressure
(mm Hg)
45 (38–51) 46 (39–59) .41
Time to ECMO from
intubation (h)
27 (12–52) 24 (12–56) .66
Mode of ECMO
VA ECMO 80 (99) 145 (97) .67*
Other mode 1 (1) 4 (3)
Arterial cannulation site .73*
Aorta 35 (57) 63 (66)
Carotid artery 19 (31) 23 (24)
Femoral artery 6 (10) 8 (9)
Other 1 (2) 1 (1)
(Continued)
TABLE 2. Continued
Variable
Survivors
n ¼ 81
Nonsurvivors
n ¼ 149
P
value
Venous cannulation site .40*
Right atrium 29 (48) 45 (48)
Internal jugular vein 15 (25) 26 (28)
Femoral vein 12 (20) 10 (11)
Other 5 (8) 12 (13)
Thoracic cannulation 36 (59) 64 (67) .29
ECMO flow at onset
(mL/kg/min)
93 (75–104) 93 (76–109) .74
Duration of ECMO (h) 99 (65–146) 145 (64–256) .003
ECMO, Extracorporeal membrane oxygenation; HFOV, high-frequency oscillatory
ventilation; NMB, neuromuscular blockade; ECPR, extracorporeal cardiopulmonary
resuscitation; PaCO2, partial pressure of carbon dioxide; PAO2, partial pressure of ox-
ygen; FIO2, fraction of inspired oxygen concentration; PIP, peak inflation pressure;
PEEP, positive end-expiratory pressure; MAP, mean airway pressure. Missing obser-
vations (pH: 30; PCO2: 31; PO2: 31; standarized bicarbonate: 51; FIO2: 45; PIP: 44;
PEEP: 90; mean arterial pressure: 148: systolic blood pressure: 63; diastolic blood
pressure: 66; mean arterial pressure: 86; intubation to ECMO: 18; arterial cannulation
site: 74; venous cannulation site: 74; left atrial vent: 74; ECMO flow at onset: 96).
*Fisher exact test.
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DPre-extracorporeal membrane oxygenation and extra-
corporeal membrane oxygenation support data. Table
2 shows differences in pre-ECMO and initial ECMO
parameters between survivors and nonsurvivors. The inci-
dence of cardiac arrest before ECMO cannulation (not
ECPR) was significantly higher in nonsurvivors compared
with survivors. The need for inotrope support, temporary
cardiac pacing, intravenous bicarbonate administration,
use of advanced respiratory support therapies (eg, inhaledThe Journal of Thoracic and Canitric oxide and high-frequency oscillatory ventilation) be-
fore ECMO deployment, and duration of ventilation before
ECMO were not significantly different between survivors
and nonsurvivors. Although ventilator settings before
ECMO were similar between the 2 groups, nonsurvivors re-
quired a significantly higher fraction of inspired oxygen
concentration (FIO2) compared with survivors. Hemody-
namics and pre-ECMO arterial blood gas were not signifi-
cantly different between survivors and nonsurvivors.
Mortality was not associated with the use of open-chest tho-
racic cannulation technique or specific arterial and venous
cannulation sites. Duration of ECMO support in survivors
was significantly shorter in survivors than nonsurvivors.
Extracorporeal membrane oxygenation complications.
Table 3 shows differences in the incidence of ECMO com-
plications between survivors and nonsurvivors. Surgical
bleeding, CNS injury, renal failure, need for support with
intravenous inotropes while on ECMO, and presence of
bloodstream infections during ECMO occurred more fre-
quently in nonsurvivors compared with survivors. There
was a trend toward a higher incidence of hyperglycemia
and gastrointestinal complications in nonsurvivors com-
pared with survivors. Mechanical problems, such as
circuit-related complications and circuit thrombus, were
not different for survivors compared with nonsurvivors.
Multivariable logistic regression model of factors associ-
ated with mortality. Table 4 shows the results of a multi-
variable logistic regression model developed to evaluate
factors associated with in-hospital mortality. Candidate var-
iables for inclusion in the multivariable model included pre-
ECMO FIO2, surgical bleeding, CNS injury, renal failure,
need for intravenous inotropes while on ECMO, cardiac
tamponade, bloodstream infection, hyperglycemia, gastro-
intestinal complications while supported with ECMO, andrdiovascular Surgery c Volume 142, Number 3 507
TABLE 3. Complications in patients supported with extracorporeal
membrane oxygenation after the Fontan operation
Complications
Survivors
n ¼ 81
Nonsurvivors
n ¼ 149
P
value
Mechanical complications 16 (20) 41 (28) .19
Circuit related 10 (12) 27 (18)
Air in circuit 2 (3) 5 (3)
Cannula related 4 (5) 18 (12)
Circuit thrombus 13 (16) 24 (16) .99
Surgical bleeding 23 (28) 69 (43) .01
Neurologic injury 6 (7) 40 (27) <.001
Brain death 0 (0) 17 (11)
Seizures 4 (5) 15 (10)
Cerebral infarction 2 (3) 5 (3)
Intracranial bleed 1 (1) 9 (6)
Renal failure 18 (22) 71 (48) <.001
Serum creatinine>1.5 mg/dL 11 (14) 49 (33)
Renal replacement therapy 14 (17) 44 (30)
ECMO related
Need for inotropes on ECMO 49 (61) 109 (73) .05
CPR on ECMO 1 (1) 5 (3) .67
pH<7.2 on ECMO 2 (3) 6 (4) .72
Cardiac complications
Arrhythmia 17 (21) 31 (21) .98
Tamponade during ECMO 1 (1) 9 (6) .10
Respiratory complications 5 (6) 10 (7) .87
Pulmonary hemorrhage 3 (4) 7 (5)
Pneumothorax 2 (3) 5 (3)
Bloodstream infection 4 (5) 20 (13) .04
Metabolic complications
Hypoglycemia (blood
glucose<40 mg/dL)
0 (0) 4 (3) .14
Hyperglycemia (blood glucose
>240 mg/dL)
7 (9) 26 (17) .07
Gastrointestinal complications 2 (3) 12 (8) .09
Gastrointestinal hemorrhage 1 (1) 5 (3)
Hyperbilirubinemia 1 (1) 7 (5)
ECMO, Extracorporeal membrane oxygenation; CPR, cardiopulmonary resusci-
tation.
TABLE 4. Factors associated with mortality in patients supported
with extracorporeal membrane oxygenation after the Fontan
operation
Variable OR 95% CI df, P value
Surgical bleeding 2.36 1.22–4.56 1, .01
Neurologic complication 5.18 1.97–13.61 1, .001
Renal failure 2.81 1.41–5.59 1, .003
Duration of ECMO (h) 3, .003
65 Reference
>65–119 0.33 0.14–0.76 .01
>119–211 0.71 0.30–1.69 .44
>211 1.72 0.67–4.43 .27
OR, Odds ratio; CI, confidence interval; ECMO, extracorporeal membrane oxygena-
tion. n ¼ 230; model area under curve: 0.77.
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Dduration of ECMO. Neurologic complications (OR, 5.18;
95% confidence interval [CI], 1.97–13.61; P ¼ .001), sur-
gical bleeding (OR, 2.36; 95% CI, 1.22–4.56; P ¼ .01),
and renal failure (OR, 2.81; CI, 1.41–5.59; P ¼ .003)
were independently associated with increased odds of mor-
tality. ECMO duration was evaluated after categorizing the
variable into quartiles. The second quartile of ECMO dura-
tion (>65 to 119 hours) was independently associated
with decreased odds of mortality compared with ECMO du-
ration values in the first quartile. The curvilinear association
of adjusted mortality for the study population and ECMO
support duration using generalized additive modeling
technique is illustrated in Figure 2.
DISCUSSION
The use of ECMO to support cardiac failure after the
Fontan operation has increased over time. By using ELSO508 The Journal of Thoracic and Cardiovascular Surgregistry data from 1987 to 2009, we found that only 35%
of these patients survived to hospital discharge. Variables as-
sociated with increased mortality included neurologic com-
plications, surgical bleeding, and renal failure. Patients
supported with ECMO for approximately 3 to 5 days had in-
creased odds of survival comparedwith shorter ECMO dura-
tion. In our analysis, morality was higher in patients with
complications that developed during the course of ECMO,
but not associated with demographic, pre-ECMO support,
and ECMO support variables. This suggests that ECMO
complicationsmay limit survival outcomes for these patients.
Previously published survivals after ECMO support of
patients who have undergone the Fontan operation are vari-
able. In a total of 39 patients supported with ECMO after the
Fontan operations, compiled from published case reports
and small patient series, 18 (46%) survived to hospital dis-
charge.1,3-8,10,11,14-21 In a series of Fontan case subjects
(n ¼ 14) from a single institution, Booth and colleagues14
reported a survival of 50%. Our reported survival to hospi-
tal discharge rate of 35%, however, is considerably lower.
This may be related to the multi-institutional nature of
our data reflecting considerable variability in ECMO indi-
cations, timing of ECMO deployment, and management
of patients on ECMO between institutions. However, we
think our estimate of survival for patients supported with
ECMO after the Fontan operation may be a more accurate
estimate because of the large number of patients available
for analysis.
The survival of 35% for patients supported with ECMO
after the Fontan operation in the current study is lower than
the 47% overall survival reported by the ELSO registry for
ECMO used to support pediatric cardiac patients during the
same time period.22 Patients with the Fontan circulation
pose unique and difficult challenges for ECMO support
that may decrease survival in these patients. The anatomy
of the cavopulmonary connection in patients who have un-
dergone the Fontan operation may limit venous drainage
and preclude adequate decompression of the heart. The con-
sequent need for multiple venous cannulations complicatesery c September 2011
FIGURE 2. Relation of ECMO duration and mortality. Fitted values for
ECMOdurationwere derived fromageneralizedadditivemodel of factors as-
sociated with mortality. The model was adjusted for surgical bleeding, CNS
injury, and renal failure. The solid line was plotted using locally weighted
scatterplot smoothing and shows the curvilinear relationship of ECMO
duration and mortality. ECMO, Extracorporeal membrane oxygenation.
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tral venous pressures frequently seen in patients who have
undergone the Fontan operation can result in increased sus-
ceptibility to end-organ injury before and during ECMO.
Furthermore, severe ventricular dysfunction present before
ECMOmay not recover sufficiently during a short course of
cardiac support. These factors either in combination or in
isolation may lead to end-organ dysfunction or inhibit ven-
tricular recovery and thus contribute to patient mortality.
The trend of improved survival over time may indicate
that knowledge of how to support these patients with
ECMO may be improving, or that ECMO may be more
readily deployed before the onset of severe multiorgan dys-
function in some patients. Unfortunately, these factors can-
not be delineated clearly from the available registry data.
In their report of patients supported with ECMO after the
Fontan operation, Booth and colleagues14 report that those
patients with an acute and reversible cause for their severe
cardiac dysfunction are more likely to benefit from
ECMO than those with severe long-standing myocardial
dysfunction or patients who require resuscitation or
ECPR. The ELSO registry does not collect detailed infor-
mation on cardiovascular function before ECMO deploy-
ment to carefully evaluate these issues. We did not find
severity of metabolic acidosis as reflected by arterial blood
gas pH to be significantly associated with mortality.
Although we were surprised to find that ECPR (ie, ECMO
deployed during active CPR) was not associated with pa-
tient survival, nonsurvivors had an increased incidence of
cardiac arrest during their hospital course before ECMO
cannulation. As previously stated, the presence of higher
central venous pressure in patients with failing Fontan phys-
iology may increase the risk of CNS and end-organ injury
during CPR, thus limiting survival even after ECMO
deployment.9,23 Although not statistically significant, onlyThe Journal of Thoracic and Ca17 (25%) of 68 patients who received pre-ECMO CPR in
this cohort survived to hospital discharge. Therefore, initia-
tion of ECMO before cardiac arrest may be important in
promoting survival in this population.
Complications that occur during the conduct of ECMO
have been shown to decrease survival in all patient popula-
tions. Similar to prior reports of ECMO use in children with
cardiac dysfunction, our analysis demonstrated that renal
failure and CNS injury increased odds of mortality. These
complications similarly decrease survival in patients
supported with ECMO after the Fontan operation. We
also found that surgical bleeding requiring intervention de-
creased odds of survival. Surgical bleeding is common in
patients supported with ECMO, particularly those in the
postoperative period.11,13,16 Patients who have undergone
the Fontan operation may have a higher propensity to
bleed secondary to increased central venous pressure,
with consequent liver dysfunction leading to a deficiency
of coagulation factors.24 Careful anticoagulation manage-
ment, coagulation factor replacement, and attention to sur-
gical hemostasis may decrease the risk of surgical and
systemic bleeding (ie, CNS), and decrease the odds of
mortality in these patients.
The curvilinear relationship of ECMO duration and
survival is interesting and may reflect some of the issues re-
garding timing of ECMO deployment discussed previously.
We found that the odds of mortality were lowest in patients
supported with ECMO for more than 65 hours but success-
fully weaned from ECMO at or before 119 hours. The odds
of mortality were not significantly different in patients who
were supported with ECMO for more than 119 hours com-
pared with those supported for less than 65 hours. We spec-
ulate that many patients supported for less than 65 hours had
significant neurologic or other organ dysfunction at the time
of ECMO deployment, and were therefore deemed not to be
candidates for continuation of ECMO, and subsequently
died when ECMO was withdrawn. Patients who required
longer duration of ECMO support may have had higher
odds of mortality from irreversible cardiac failure or the
onset of ECMO complications. It is therefore important to
deploy ECMO in a timely fashion before the onset of irre-
versible end-organ injury and investigate and treat any
reversible causes of cardiac dysfunction as quickly as
possible so that these patients can be weaned off ECMO
expeditiously.
The results presented from this analysis should be inter-
preted after consideration of the limitations of the data. The
ELSO registry data are retrospective and include patients
from many reporting centers where experience, indications,
patient selection, and management of ECMOmay vary con-
siderably. The data-collection instrument is not designed
specifically for use with Fontan case subjects; thus, impor-
tant variables that may be associated with mortality in this
population may not have been collected. For example,rdiovascular Surgery c Volume 142, Number 3 509
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Dtime from surgery to onset of ECMO support was not avail-
able for analysis. Missing data for some variables precluded
their use. Finally, important long-term neurologic and func-
tional data are not collected by the ELSO registry. Despite
these limitations, this report contains the largest cohort of
Fontan case subjects supported with ECMO to date. It con-
tains useful information about mortality in Fontan case sub-
jects supported with ECMO and may provide guidelines for
planning additional studies.
CONCLUSIONS
Patients supported with ECMO after the Fontan opera-
tion have a survival to hospital discharge rate of 35%.
ECMO complications, including surgical bleeding, renal
failure, and CNS injury, decrease survival in these patients.
Consideration of early ECMO deployment and correction
of surgical bleeding in Fontan case subjects before the onset
of end-organ injury may improve survival in these high-risk
patients. In addition, the benefits of alternative forms of me-
chanical support, including short- or long-term ventricular
assist devices in patients with cardiac dysfunction after
the Fontan operation, should be studied in the future. The
trend toward improved mortality over the study period
encourages continued investigation and amelioration of
factors associated with mortality in these patients.
References
1. Delius RE, Bove EL, Meliones JN, Custer JR, Moler FW, Crowley D, et al. The
use of extracorporeal life support in children with congenital heart disease. Crit
Care Med. 1992;20:1216-22.
2. Morris MC, Ittenbach RF, Godinez RI, Portnoy JD, Tabbutt S, Hanna BD, et al.
Risk factors for mortality in 137 pediatric cardiac intensive care unit patients
managed with extracorporeal membrane oxygenation. Crit Care Med. 2004;
32:1061-9.
3. Kulik TJ, Moler FW, Palmisano JM, Custer J, Mosca R, Bove E, et al. Outcome-
associated factors in pediatric patients treated with extracorporeal membrane
oxygenator after cardiac surgery. Circulation. 1996;94(suppl):II63-8.
4. Alsoufi B, Shen I, Karamlou T, Ciacomuzzi C, Burch G, Silberbach M, et al.
Extracorporeal life support in neonates, infants, and children after repair of con-
genital heart disease: modern era results in a single institution. Ann Thorac Surg.
2005;80:15-21.
5. Aharon AS, Davis C, Drinkwater DC Jr, Churchwell KB, Quisling SV, Reddy S,
et al. Extracorporeal membrane oxygenation in children after repair of congenital
heart lesions. Ann Thorac Surg. 2001;72:2095-101.510 The Journal of Thoracic and Cardiovascular Surg6. Ziomek S, Harrell JE Jr, Fasules JW, Faulkner SC, Chipman CW, Moss M, et al.
Extracorporeal membrane oxygenation for cardiac failure after congenital heart
operation. Ann Thorac Surg. 1992;54:861-7.
7. Kanter KR, Pennington DG, Weber TR, Zambie MA, Braun P, Martychenko V.
Extracorporeal membrane oxygenation for postoperative cardiac support in
children. J Thorac Cardiovasc Surg. 1987;93:27-35.
8. Duncan BW, Hraska V, Jonas RA, Wessel DL, del Nido PJ, Laussen PC, et al.
Mechanical circulatory support in children with cardiac disease. J Thorac
Cardiovasc Surg. 1999;117:529-42.
9. Thiagarajan RR, Laussen PC, Rycus PT, Bartlett RH, Bratton SL. Extracorporeal
membrane oxygenation to aid cardiopulmonary resuscitation in infants and Chil-
dren’s Hospital Boston. Circulation. 2007;116:1693-700.
10. Dalton H, Rycus PT, Conard SA. Update on extracorporeal life support 2004.
Semin Perinatol. 2005;29:24-33.
11. Klein MD, Shaheen KW,Whittlesey GC, PinskyWW, Arciniegas E. Extracorpo-
real membrane: oxygenation for the circulatory support of children after repair of
congenital heart disease. J Thorac Cardiovasc Surg. 1990;100:498-505.
12. Cooper DS, Jacobs JP, Moore L, Stock A, Gaynor JW, Chancy T, et al. Cardiac
extracorporeal life support: state of the art in 2007. Cardiol Young. 2007;
17(Suppl 2):104-15.
13. Mayer JE, Hedson H, Jonas RA, Lang P, Fargas FJ, Cook N, et al. Extending the
limits for modified Fontan procedures. J Thorac Cardiovasc Surg. 1986;92:
1021-8.
14. Booth KL, Roth SJ, Thiagarajan RR, Almodovar MC, del Nido PJ, Laussen PC.
Extracorporeal membrane oxygenation support of the Fontan and bidirectional
Glenn circulation. Ann Thorac Surg. 2004;77:1341-8.
15. Meliones JN, Custer JR, Snedecor S, Moler FW, O’Rourke P, Delius RE. Extra-
corporeal life support for cardiac assist in pediatric patients-review of ELSO
Registry Data. Circulation. 1991;84(suppl III):III168-72.
16. Saito A, Miyamura H, Kanazawa H, Ohzeki H, Eguchi S. Extracorporeal mem-
brane oxygenation for severe heart failure after Fontan operation. Ann Thorac
Surg. 1993;55:153-5.
17. Suzuki Y, Yamauchi S, Daitoku K, Fukui K, Fukuda I. Extracorporeal membrane
oxygenation circulatory support after congenital cardiac surgery. ASAIO J. 2009;
55:53-7.
18. Jaggers JJ, Forbess JM, Shah AS, Meliones JN, Kirshbom PM, Miller CE, et al.
Extracorporeal membrane oxygenation for infant postcardiotomy support:
significance of shunt management. Ann Thorac Surg. 2000;69:1476-83.
19. Preciado D, Verghese S, Choi S. Aggressive bronchoscopic management of
plastic bronchitis. Int J Pediatr Otorhinolaryngol. 2010;74:820-2.
20. Chaudhari M, Sturman J, O’Sullivan J, Smith J, Wrightson N, Parry G, et al.
Rescue cardiac transplantation for early failure of the Fontan-type circulation
in children. J Thorac Cardiovasc Surg. 2005;129:416-22.
21. Bedard E, Lopez S, Perron J, Houde C, Couture C, Vaillancourt R, et al. Life
threatening hemoptysis following the Fontan procedure. Can J Cardiol. 2008;
24:145-7.
22. ECMO registry of the Extracorporeal Life Support Organization. Available at:
http://www.elso.med.umich.edu/Support.html. Accessed July 2010.
23. Salvin JW, Scheurer MA, Laussen PC, Mayer JE Jr, Del Nido PJ, Pigula FA, et al.
Factors associated with prolonged recovery after the Fontan operation.
Circulation. 2008;118(14 Suppl):S171-6.
24. Bull K. The Fontan procedure: lesions learned from the past. Heart. 1998;79:
213-4.ery c September 2011
